JP Morgan Downgrades Mereo BioPharma Group to Underweight

Benzinga Newsdesk www.benzinga.com Negative 89.5%

Neg 89.5% Neu 0% Pos 0%

JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.

Comments

No comments yet. Be the first!